<DOC>
	<DOC>NCT02448628</DOC>
	<brief_summary>This study is a multi-center, open label, dose titration, exploratory study to evaluate efficacy and safety of CS-3150 in Japanese hypertensive patients with moderate renal impairment. Primary endpoint is change from baseline in sitting systolic and diastolic blood pressure.</brief_summary>
	<brief_title>A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<criteria>Men and women Aged 20 years or older and 80 years or younger at informed consent Subjects with hypertension (Sitting systolic blood pressure SBP &gt;= 140 mmHg and &lt; 180 mmHg, Sitting diastolic blood pressure DBP &gt;= 80 mmHg and &lt; 110 mmHg) estimated glomerular filtration rate eGFR &gt;= 30 mL/min/1.73 m2 and &lt; 60 mL/min/1.73 m2 Secondary hypertension or malignant hypertension Diabetes mellitus with albuminuria Serum potassium level &lt; 3.5 or &gt;= 5.1 mEq/L Subjects under Insulin treatment Subjects under or preplanned for hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>moderate renal impairment</keyword>
	<keyword>mineralocorticoid receptor antagonist</keyword>
	<keyword>CS-3150</keyword>
	<keyword>Japanese</keyword>
</DOC>